Measles pp 191-212 | Cite as

Measles: Old Vaccines, New Vaccines

  • D. E. GriffinEmail author
  • C. -H. Pan
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 330)

Isolation of measles virus in tissue culture by Enders and colleagues in the 1960s led to the development of the first measles vaccines. An inactivated vaccine provided only short-term protection and induced poor T cell responses and antibody that did not undergo affinity maturation. The response to this vaccine primed for atypical measles, a more severe form of measles, and was withdrawn. A live attenuated virus vaccine has been highly successful in protection from measles and in elimination of endemic measles virus transmission with the use of two doses. This vaccine is administered by injection between 9 and 15 months of age. Measles control would be facilitated if infants could be immunized at a younger age, if the vaccine were thermostable, and if delivery did not require a needle and syringe. To these ends, new vaccines are under development using macaques as an animal model and various combinations of the H, F, and N viral proteins. Promising studies have been reported using DNA vaccines, subunit vaccines, and virus-vectored vaccines.


Rhesus Macaque Measle Virus Measle Vaccine Measle Vaccination Modify Vaccinia Virus Ankara 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aaby P, Samb B, Simondon F, Knudsen K, Seck AM, Bennett J, Markowitz L, Whittle H (1996) A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Trans R Soc Trop Med Hyg 90:326–330PubMedGoogle Scholar
  2. Aaby P, Jensen H, Samb B, Cisse B, Sodemann M, Jakobsen M, Poulsen A, Rodrigues A, Lisse IM, Simondon F, Whittle H (2003a) Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 361:2183–2188Google Scholar
  3. Aaby P, Jensen H, Simondon F, Whittle H (2003b) High-titer measles vaccination before 9 months of age and increased female mortality: do we have an explanation? Semin Pediatr Infect Dis 14:220–232Google Scholar
  4. Aaby P, Ibrahim SA, Libman MD, Jensen H (2006) The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa. Vaccine 24:2764–2771PubMedGoogle Scholar
  5. Ad Hoc Advisory Committee on Measles Control (1963) Statement of the status of measles vaccines. JAMA 183:1112–1113Google Scholar
  6. Albrecht P, Ennis FA, Saltzman EJ, Krugman S (1977) Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 91:715–718PubMedGoogle Scholar
  7. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC (1996) Secondary failure rates of measles vaccines: a metaanalysis of published studies. Pediatr Infect Dis J 15:62–66PubMedGoogle Scholar
  8. Angel JB, Walpita P, Lerch RA, Sidhu MS, Masurekar M, DeLellis RA, Noble JT, Snydman DR, Udem SA (1998) Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 129:104–106PubMedGoogle Scholar
  9. Auwaerter PG, Rota PA, Elkins WR, Adams RJ, DeLozier T, Shi Y, Bellini WJ, Murphy BR, Griffin DE (1999) Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 180:950–958PubMedGoogle Scholar
  10. Bellanti JA, Sanga RL, Klutinis B, Brandt B, Artenstein MS (1969) Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines. N Engl J Med 280:628–633PubMedGoogle Scholar
  11. Bellini WJ, Rota JS, Rota PA (1994) Virology of measles virus. J Infect Dis 170:S15–S23PubMedGoogle Scholar
  12. Bitnun A, Shannon P, Durward A, Rota PA, Bellini WJ, Graham C, Wang E, Ford-Jones EL, Cox P, Becker L, Fearon M, Petric M, Tellier R (1999) Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 29:855–861PubMedGoogle Scholar
  13. Black FL, Sheridan SR (1960) Studies on an attenuated measles-virus vaccine. N Engl J Med 263:165–169PubMedGoogle Scholar
  14. Boorsma M, Saudan P, Pfruender H, Bailey JE, Schlesinger S, Renner WA, Bachmann MF (2003) Alphavirus cDNA-based expression vectors: effects of RNA transcription and nuclear export. Biotechnol Bioeng 81:553–562PubMedGoogle Scholar
  15. Brena AE, Cooper ER, Cabral HJ, Pelton SI (1993) Antibody response to measles and rubella vaccine by children with HIV infection. J Acquir Immune Defic Syndr 6:1125–1129PubMedGoogle Scholar
  16. Budka H, Urbanits S, Liberski PP, Eichinger S, Popow-Kraupp T (1996) Subacute measles virus encephalitis: a new and fatal opportunistic infection in a patient with AIDS. Neurology 46:586–587PubMedGoogle Scholar
  17. Buser F (1967) Side reaction to measles vaccination suggesting the Arthus phenomenon. N Engl J Med 277:250–251PubMedGoogle Scholar
  18. Caceres VM, Strebel PM, Sutter RW (2000) Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 31:110–119PubMedGoogle Scholar
  19. Cardoso AI, Blixenkrone-Moller M, Fayolle J, Liu M, Buckland R, Wild TF (1996) Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity. Virology 225:293–299PubMedGoogle Scholar
  20. Carter CH, Conway TJ, Cornfeld D, Iezzoni DG, Kempe CH, Moscovici C, Rauh LW, Vignec AJ, Warren J (1962) Serologic response of children to inactivated measles vaccine. JAMA 179:848–853PubMedGoogle Scholar
  21. Centers for Disease Control (1988) Measles in HIV-infected children, United States. MMWR 37:183–186Google Scholar
  22. Centers for Disease Control (2000) Recommendations from meeting on strategies for improving global measles control, May 11–12, 2000. MMWR 49 (12):1116–1118Google Scholar
  23. Centers for Disease Control (2006) Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006–2015. MMWR Morb Mortal Wkly Rep 55:511–515Google Scholar
  24. Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, Ward BJ (2005) A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23:1374–1383PubMedGoogle Scholar
  25. Chatterji M, Mankad V (1977) Failure of attenuated viral vaccine in prevention of atypical measles. JAMA 238:2635PubMedGoogle Scholar
  26. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162:1036–1042PubMedGoogle Scholar
  27. Christenson B, Bottiger M (1994) Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 12:129–133PubMedGoogle Scholar
  28. Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77:11546–11554PubMedGoogle Scholar
  29. Committee on Infectious Diseases and Committee on Pediatric AIDS (1999) Measles immunization in HIV-infected children. Pediatrics 103:1057–1060Google Scholar
  30. ondack C, Grivel JC, Devaux P, Margolis L, Cattaneo R (2007) Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. J Infect Dis 196: 541–549Google Scholar
  31. Cutts FT, Markowitz LE (1994) Successes and failures in measles control. J Infect Dis 170: S32–S41PubMedGoogle Scholar
  32. Cutts FT, Grabowsky M, Markowitz LE (1995) The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 23:95–106PubMedGoogle Scholar
  33. Cutts FT, Clements CJ, Bennett JV (1997) Alternative routes of measles immunization: a review. Biologicals 25:323–338PubMedGoogle Scholar
  34. Cutts FT, Henao-Restrepo A, Olive JM (1999) Measles elimination: progress and challenges. Vaccine 17 [Suppl 3]:S47–S52PubMedGoogle Scholar
  35. de Quadros CA, Izurieta H, Venczel L, Carrasco P (2004) Measles eradication in the Americas: progress to date. J Infect Dis 189 [Suppl 1]:S227–S235PubMedGoogle Scholar
  36. de Swart RL, Kuiken T, Fernandez-de Castro J, Papania MJ, Bennett JV, Valdespino JL, Minor P, Witham CL, Yuksel S, Vos H, van Amerongen G, Osterhaus AD (2006) Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 24:6424–6436PubMedGoogle Scholar
  37. de Swart RL, LiCalsi C, Quirk AV, van Amerongen G, Nodelman V, Alcock R, Yuksel S, Ward GH, Hardy JG, Vos H, Witham CL, Grainger CI, Kuiken T, Greenspan BJ, Gard TG, Osterhaus AD (2007) Measles vaccination of macaques by dry powder inhalation. Vaccine 25:1183–1190PubMedGoogle Scholar
  38. de Vries P, Van Binnendijk RS, Van der Marel P, Van Wezel AL, Voorma HO, Sundquist B, UytdeHaag FG, Osterhaus AD (1988) Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. J Gen Virol 69:549–559PubMedGoogle Scholar
  39. Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G (2000) Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 7:2105–2112PubMedGoogle Scholar
  40. Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan DT, Donnelly JJ, III, Ott G, McDonald DM (2003) Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 225:12–20PubMedGoogle Scholar
  41. Dhiman N, Ovsyannikova IG, Cunningham JM, Vierkant RA, Kennedy RB, Pankratz VS, Poland GA, Jacobson RM (2007) Associations between measles vaccine immunity and single-nucle-otide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 195:21–29PubMedGoogle Scholar
  42. Dubensky T, Driver D, Polo J, Belli B, Latham E, Ibanez C, Chada S, Brumm D, Banks T, Mento S, Jolly D, Chang S (1996) Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 70:508–519PubMedGoogle Scholar
  43. Eghafona NO, Ahmad AA, Ezeokoli CD, Emejuaiwe SO (1991) Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination. Microbios 68:33–36Google Scholar
  44. El Kasmi KC, Muller CP (2001) New strategies for closing the gap of measles susceptibility in infants: towards vaccines compatible with current vaccination schedules. Vaccine 19: 2238–2244PubMedGoogle Scholar
  45. El Mubarak HS, Yuksel S, van Amerongen G, Mulder PG, Mukhtar MM, Osterhaus AD, de Swart RL (2007) Infection of cynomolgus macaques ( Macaca fascicularis ) and rhesus macaques ( Macaca mulatta ) with different wild-type measles viruses. J Gen Virol 88:2028–2034PubMedGoogle Scholar
  46. Enders JF, Peebles TC (1954) Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med 86:277–286PubMedGoogle Scholar
  47. Enders JF, Katz SL, Holloway A (1962) Development of attenuated measles-virus vaccines. Am J Dis Child 103:335–340PubMedGoogle Scholar
  48. Enders JF, Katz SL, Milovanovic M V, Holloway A (1960) Studies of an attenuated measles virus vaccine: I. Development and preparation of the vaccine: technics for assay of effects of vaccination. N Engl J Med 263:153–159PubMedGoogle Scholar
  49. Endo A, Izumi H, Miyashita M, Taniguchi K, Okubo O, Harada K (2001) Current efficacy of pos-texposure prophylaxis against measles with immunoglobulin. J Pediatr 138:926–928PubMedGoogle Scholar
  50. Ertl OT, Wenz DC, Bouche FB, Berbers GA, Muller CP (2003) Immunodominant domains of the measles virus hemagglutinin protein eliciting a neutralizing human B cell response. Arch Virol 148:2195–2206PubMedGoogle Scholar
  51. Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D (1997) Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 78:1577–1580PubMedGoogle Scholar
  52. Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG (2007) Local development of effector and memory T helper cells. Curr Opin Immunol 19:259–267PubMedGoogle Scholar
  53. Feldman HA, Novack A, Warren J, Haute T (1962) Inactivated measles virus vaccine. II. Prevention of natural and experimental measles with the vaccine. JAMA 179:391–397PubMedGoogle Scholar
  54. Fooks AR, Jeevarajah D, Warnes A, Wilkinson GW, Clegg JC (1996) Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene. Viral Immunol 9:65–71PubMedGoogle Scholar
  55. Fulginiti V, Kempe CH (1963) Measles exposure among vaccine recipients. Am J Dis Child 160:62–73Google Scholar
  56. Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075–1080PubMedGoogle Scholar
  57. Fulginiti VA, Arthur JH, Pearlman DS, Kempe CH (1968) Altered reactivity to measles virus: local reactions following attenuated measles virus immunization in children who previously received a combination of inactivated and attenuated vaccines. Am J Dis Child 115:67–72Google Scholar
  58. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y (1998) Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527–532PubMedGoogle Scholar
  59. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM (2004) Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 190:83–90PubMedGoogle Scholar
  60. Garenne M, Leroy O, Beau J-P, Sene I (1991) Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 338:903–907PubMedGoogle Scholar
  61. Gay NJ (2004) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189 [Suppl 1]:S27–S35PubMedGoogle Scholar
  62. Goon P, Cohen B, Jin L, Watkins R, Tudor-Williams G (2001) MMR vaccine in HIV-infected children — potential hazards? Vaccine 19:3816–3819PubMedGoogle Scholar
  63. Graves MC, Griffin DE, Johnson RT, Hirsch RL, Lindo de Soriano I, Roedenbeck S, Vaisberg A (1984) Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol 49:409–412PubMedGoogle Scholar
  64. Gremillion DH, Crawford GE (1981) Measles pneumonia in young adults: an analysis of 106 cases. Am J Med 71:539–542PubMedGoogle Scholar
  65. Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, Wloch MK, Tonsky K, Norman J, Manthorpe M, Wheeler CJ (2001) Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19:1911–1923PubMedGoogle Scholar
  66. Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, Sasaki K, Kohda D, Yanagi Y, Maenaka K (2007) Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S A 104:19535–19540PubMedGoogle Scholar
  67. Hektoen L (1905) Experimental measles. J Infect Dis 2:238–255Google Scholar
  68. Herweijer H, Latendresse JS, Williams P, Zhang G, Danko I, Schlesinger S, Wolff JA (1995) A plasmid-based self-amplifying Sindbis virus vector. Hum Gene Ther 6:1161–1167PubMedGoogle Scholar
  69. Hirayama M (1983) Measles vaccines used in Japan. Rev Infect Dis 5:495–503PubMedGoogle Scholar
  70. Holt EA, Moulton LH, Siberry GK, Halsey NA (1993) Differential mortality by measles vaccine titer and sex. J Infect Dis 168:1087–1096PubMedGoogle Scholar
  71. Home F (1759) Medical facts and experiments. Miller, LondonGoogle Scholar
  72. Hutchins SS, Dezayas A, Le Blond K, Heath J, Bellini W, Audet S, Beeler J, Wattigney W, Markowitz L (2001) Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol 154:1064–1071PubMedGoogle Scholar
  73. Jianzhi X, Zhihui C (1983) Measles vaccine in the People's Republic of China. Rev Infect Dis 5:506–510Google Scholar
  74. Kaslow DC (2004) A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. Trans R Soc Trop Med Hyg 98:593–601PubMedGoogle Scholar
  75. Katz SL, Milovanovic M V, Enders JF (1958) Propagation of measles virus in cultures of chick embryo cells. Proc Soc Exp Biol Med 97:23–29PubMedGoogle Scholar
  76. Katz SL, Enders JF, Kibrick S (1959) Immunization of children with a live attenuated measles virus. Am J Dis Child 98:605–607Google Scholar
  77. Katz SL, Enders JF, Holloway A (1960) Studies on an attenuated measles-virus vaccine. II. Clinical, virologic and immunologic effects of vaccine in institutionalized children. N Engl J Med 263:159–160PubMedGoogle Scholar
  78. Knudsen KM, Aaby P, Whittle H, Rowe M, Samb B, Simondon F, Sterne J, Fine P (1996) Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 25:665–673PubMedGoogle Scholar
  79. Krugman S (1971) Present status of measles and rubella immunization in the United States: a medical progress report. J Pediatr 78:1–16PubMedGoogle Scholar
  80. Lambert PH, Liu M, Siegrist CA (2005) Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 11:S54–S62PubMedGoogle Scholar
  81. Langedijk JPM, Daus FJ, van Oirschot JT (1997) Sequence and structure alignment of Paramyxoviridae attachment proteins and discovery of enzymatic activity for a morbillivirus hemagglutinin. J Virol 71:6155–6167PubMedGoogle Scholar
  82. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP (2003) Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9:33–39PubMedGoogle Scholar
  83. Lennon JL, Black FL (1986) Maternally derived measles immunity in era of vaccine-protected mothers. J Pediatr 108:671–676PubMedGoogle Scholar
  84. Liebert UG, Flanagan SG, Loffler S, Baczko K, ter Meulen V, Rima BK (1994) Antigenic determinants of measles virus haemagglutinin associated with neurovirulence. J Virol 68:1486–1493PubMedGoogle Scholar
  85. Low N, Kraemer S, Schneider M, Restrepo AM (2008) Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 26:383–398PubMedGoogle Scholar
  86. Maldonado YA, Lawerence EC, DeHovitz R, Hartzell H, Albrecht P (1995) Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 96:447–450PubMedGoogle Scholar
  87. Malvoisin E, Wild F (1990) Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J Virol 64:5160–5162PubMedGoogle Scholar
  88. Maris EP, Gellis SS, Shaffer F, Dunham WB, Stokes J Jr, Rake G (1949) Vaccination of children with various chorioallantoic passages of measles virus. Pediatrics 4:1–8PubMedGoogle Scholar
  89. Markowitz LE, Albrecht P, Rhodes P, Demonteverde R, Swint E, Maes EF, Powell C, Patriarca PA (1996) Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Pediatrics 97:53–58PubMedGoogle Scholar
  90. Mathias RG, Meekison WG, Arcand TA (1989) The role of secondary vaccine failures in measles outbreaks. Am J Public Health 79:475–478PubMedGoogle Scholar
  91. Mawhinney H, Allen IV, Beare JM, Bridges JH, Connolly MH, Nevin NC, Neill DW, Hobbs JR (1971) Dysgammaglobulinaemia complicated by disseminated measles. BMJ 2:380–381PubMedGoogle Scholar
  92. McLaughlin M, Thomas P, Onorato I, Rubinstein A, Oleske J, Nicholas S, Krasinski K, Guigli P, Orenstein W (1988) Live virus vaccines in human immunodeficiency virus-infected children: a retrospective survey. Pediatrics 82:229–233PubMedGoogle Scholar
  93. Measles Vaccines Committee (1968) Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. BMJ 2:449–452Google Scholar
  94. Melnick JL (1996) Thermostability of poliovirus and measles vaccines. Dev Biol Stand 87:155–160PubMedGoogle Scholar
  95. Merz DC, Scheid A, Choppin PW (1980) Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J Exp Med 151:275–288PubMedGoogle Scholar
  96. Migasena S, Simasathien S, Samakoses R, Pitisuttitham P, Heath J, Bellini W, Bennet J (1997) Adverse impact of infections on antibody responses to measles vaccination. Vaccine 15:72–77Google Scholar
  97. Milovanovic MV (1965) Live measles vaccine trials in Yugoslavia. Archges Virusforsch 16:231–242Google Scholar
  98. Milovanovic MV, Enders JF, Mitus A (1957) Cultivation of measles virus in human amnion cells and in developing chick embryo. Proc Soc Exp Biol Med 95:120–127PubMedGoogle Scholar
  99. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5:905–916PubMedGoogle Scholar
  100. Mollenkopf HJ, Dietrich G, Fensterle J, Grode L, Diehl KD, Knapp B, Singh M, O'Hagan DT, Ulmer JB, Kaufmann SH (2004) Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22:2690–2695PubMedGoogle Scholar
  101. Monafo WJ, Haslam DB, Roberts RL, Zaki SR, Bellini WJ, Coffin CM (1994) Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 124:273–276PubMedGoogle Scholar
  102. Moss WJ, Griffin DE (2006) Global measles elimination. Nat Rev Microbiol 4:900–908PubMedGoogle Scholar
  103. Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler JA, Audet SA, Ngala M, Mwangala S, Nkonga-Mwangilwa C, Ryon JJ, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT (2007) Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 196:347–355PubMedGoogle Scholar
  104. Moss WJ, Fisher C, Scott S, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts FT (2008) HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 46:523–527PubMedGoogle Scholar
  105. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 90:11307–11311PubMedGoogle Scholar
  106. Nader PR, Horwitz MS, Rousseau J (1968) Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J Pediatr 72:22–28Google Scholar
  107. Naniche D, Garenne M, Rae C, Manchester M, Buchta R, Brodine SK, Oldstone MB (2004) Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J Infect Dis 190:1387–1395PubMedGoogle Scholar
  108. Norrby E, Enders-Ruckle G, ter Meulen V (1975) Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis 132:262–269PubMedGoogle Scholar
  109. O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB (2001) Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 75:9037–9043PubMedGoogle Scholar
  110. O'Hagan DT, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby M, Wininger M, Ng P, Crawford K, Paliard X, Coates S, Houghton M (2004) Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23:672–680PubMedGoogle Scholar
  111. Oh S, Stegman B, Pendleton CD, Ota MO, Pan CH, Griffin DE, Burke DS, Berzofsky JA (2006) Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus. Virology 352:390–399PubMedGoogle Scholar
  112. Orenstein WA (2006) The role of measles elimination in development of a national immunization program. Pediatr Infect Dis J 25:1093–1101PubMedGoogle Scholar
  113. Orenstein WA, Hinman AR, Strebel PJ (2006) Measles: the need for 2 opportunities for prevention. Clin Infect Dis 42:320–321PubMedGoogle Scholar
  114. Ota MO, Ndhlovu Z, Oh S, Piyasirisilp S, Berzofsky JA, Moss WJ, Griffin DE (2007) Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8 + T cell response during measles and after vaccination. J Infect Dis 195:1799–1807PubMedGoogle Scholar
  115. Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB (2005) Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 79:8189–8200PubMedGoogle Scholar
  116. Ovsyannikova IG, Dhiman N, Jacobson RM, Vierkant RA, Poland GA (2003) Frequency of measles virus-specific CD4 + and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 10:411–416PubMedGoogle Scholar
  117. Ovsyannikova IG, Jacobson RM, Poland GA (2004) Variation in vaccine response in normal populations. Pharmacogenomics. 5:417–427PubMedGoogle Scholar
  118. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA (2006) Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 193:655–663PubMedGoogle Scholar
  119. Ozanne G, d'Halewyn M-A (1992) Secondary immune response in a vaccinated population during a large measles epidemic. J Clin Microbiol 30:1778–1782PubMedGoogle Scholar
  120. Pabst HF, Spady DW, Maruskyk RG, Carson MM, Chui LW-L, Joffres MR, Grimsrud KM (1992) Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J 11:525–529PubMedGoogle Scholar
  121. Pan CH, Valsamakis A, Colella T, Nair N, Adams RJ, Polack FP, Greer CE, Perri S, Polo JM, Griffin DE (2005) Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 102:11581–11588PubMedGoogle Scholar
  122. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, Polack FP, Singh M, O'Hagan DT, Griffin DE (2008) Dose-dependent protection against or exacerbation of disease by a polylactide glycol-ide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol 15:697–706PubMedGoogle Scholar
  123. Parker SE, Vahlsing HL, Serfilippi LM, Franklin CL, Doh SG, Gromkowski SH, Lew D, Manthorpe M, Norman J (1995) Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum. Gene Ther 6:575–590PubMedGoogle Scholar
  124. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM, Polo JM, Ulmer J, Robinson H, Sztein MB, Levine MM (2003) Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemag-glutinin, inducing specific immune responses and protection in cotton rats. J Virol 77:5209– 5217PubMedGoogle Scholar
  125. Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, Polack FP, Ward BJ, Burt D, Chabot S, Ulmer J, Barry EM, Levine MM (2007) Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin Pharmacol Ther 82:672–685PubMedGoogle Scholar
  126. Peradze T V, Smorodintsev AA (1983) Epidemiology and specific prophylaxis of measles. Rev Infect Dis 5:487–490PubMedGoogle Scholar
  127. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letvin NL (2003) Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 77:4396–4400PubMedGoogle Scholar
  128. Plowright W, Ferris RD (1962) Studies with rinderpest virus in tissue culture: the use of attenuated cultured virus as a vaccine for cattle. Res Vet Sci 3:172–182Google Scholar
  129. Polack FP, Auwaerter PG, Lee S-H, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE (1999) Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 5:629–634PubMedGoogle Scholar
  130. Polack F, Lee S, Permar S, Manyara E, Nousari H, Jeng Y, Mustafa F, Valsamakis A, Adams R, Robinson H, Griffin D (2000) Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 6:776–781PubMedGoogle Scholar
  131. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE (2003a) A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 9:1209–1213Google Scholar
  132. Polack FP, Hoffman SJ, Moss WJ, Griffin DE (2003b) Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J Infect Dis 187:1794–1800Google Scholar
  133. Premenko-Lanier M, Rota P, Rhodes G, Bellini W, McChesney M (2004) Prior DNA vaccination does not interfere with the live-attenuated measles vaccine. Vaccine 22:762–765PubMedGoogle Scholar
  134. Premenko-Lanier M, Hodge G, Rota P, Tamin A, Bellini W, McChesney M (2006) Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 350:429–432PubMedGoogle Scholar
  135. Rauh LW, Schmidt R (1965) Measles immunization with killed virus vaccine. Am J Dis Child 109:232–237PubMedGoogle Scholar
  136. Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE (2004) Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 189 [Suppl 1]:S116–S122PubMedGoogle Scholar
  137. Reilly CM, Stokes J Jr, Buynak EB, Goldner H, Hilleman MR (1961) Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization. N Engl J Med 265:165–169PubMedGoogle Scholar
  138. Rota JS, Hummel KB, Rota PA, Bellini WJ (1992) Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology 188:135–142PubMedGoogle Scholar
  139. Rota JS, Wang ZD, Rota PA, Bellini WJ (1994) Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 31:317–330PubMedGoogle Scholar
  140. Rota PA, Liffick SL, Rota JS, Katz RS, Redd S, Papania M, Bellini WJ (2002) Molecular epidemiology of measles viruses in the United States, 1997–2001. Emerg Infect Dis 8:902–908PubMedGoogle Scholar
  141. Rudy BJ, Rutstein RM, Pinto-Martin J (1994) Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr 125:72–74PubMedGoogle Scholar
  142. Sabin AB (1991) Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur J Epidemiol 7:1–22PubMedGoogle Scholar
  143. Sabin AB, Arechiga AF, de Castro JF, Sever JL, Madden DL, Shekarchi I, Albrecht P (1983) Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. JAMA 249:2651–2662PubMedGoogle Scholar
  144. Sabin AB, Albrecht P, Takeda AK, Ribeiro EM, Veronesi R (1985) High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis 152:1231–1237PubMedGoogle Scholar
  145. Sakata H, Hirayama M, Kimura M (1978) A ten-year follow-up study on measles vaccination in Japan: evaluation of the efficacy analyzed on a computer system. Japan. J Med Sci Biol 31:339–356Google Scholar
  146. Schwarz AJF (1962) Preliminary tests of a highly attenuated measles vaccine. Am J Dis Child 103:216–219Google Scholar
  147. Schwarz AJF, Zirbel LW (1959) Propagation of measles virus in non-primate tissue culture. I. Propagation in bovine kidney tissue culture. Proc Soc Exp Biol Med 102:711–714PubMedGoogle Scholar
  148. Seng R, Samb B, Simondon F, Cisse B, Soumare M, Jensen H, Bennett J, Whittle H, Aaby P (1999) Increased long term mortality associated with rash after early measles vaccination in rural Senegal. Pediatr Infect Dis J 18:48–52PubMedGoogle Scholar
  149. Stittelaar KJ, Boes J, Kersten GF, Spiekstra A, Mulder PG, de Vries P, Roholl PJ, Dalsgaard K, van den DG, van Alphen L, Osterhaus AD (2000a) In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 18:2482–2493Google Scholar
  150. Stittelaar KJ, Wyatt LS, de Swart RL, Vos HW, Groen J, van Amerongen G, Van Binnendijk RS, Rozenblatt S, Moss B, Osterhaus AD (2000b) Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 74:4236–4243Google Scholar
  151. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der KT, Wyatt LS, Moss B, Osterhaus AD (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700–3709PubMedGoogle Scholar
  152. Stittelaar KJ, de Swart RL, Vos HW, van Amerongen G, Agafonov AP, Nechaeva EA, Osterhaus AD (2002a) Enteric administration of a live attenuated measles vaccine does not induce protective immunity in a macaque model. Vaccine 20:2906–2912Google Scholar
  153. Stittelaar KJ, de Swart RL, Vos HW, van Amerongen G, Sixt N, Wild TF, Osterhaus AD (2002b) Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine 20:2022–2026Google Scholar
  154. Stittelaar KJ, Vos HW, van Amerongen G, Kersten GF, Osterhaus AD, de Swart RL (2002c) Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates. Vaccine 21:155–157Google Scholar
  155. Stokes J Jr, Hilleman MR, Weibel RE, Buynak EB, Halenda R, Goldner H (1961) Efficacy of live, attenuated measles-virus vaccine given with human immune globulin. A preliminary report. N Engl J Med 265:507–513Google Scholar
  156. Van Binnendijk RS, van der Heijden RWJ, van Amerongen G, Uytdehaag FGCM, Osterhaus ADME (1994) Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis 170:443–448PubMedGoogle Scholar
  157. Van Binnendijk RS, van der Heijden RWJ, Osterhaus ADME (1995) Monkeys in measles research. Curr Top Microbiol Immunol 191:135–148PubMedGoogle Scholar
  158. Van Binnendijk RS, Poelen MCM, van Amerongen G, de Vries P, Osterhaus ADME (1997) Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis 175:524–532PubMedGoogle Scholar
  159. Varsanyi TM, Morein B, Love A, Norrby E (1987) Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein. J Virol 61:3896–3901PubMedGoogle Scholar
  160. Warren J, Gallian MJ (1962) Concentrated inactivated measles-virus vaccine: preparation and antigenic potency. Am J Dis Child 103:248–253Google Scholar
  161. Webster DE, Cooney ML, Huang Z, Drew DR, Ramshaw IA, Dry IB, Strugnell RA, Martin JL, Wesselingh SL (2002) Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol 76:7910–7912PubMedGoogle Scholar
  162. World Health Organization (1990) Expanded programme on immunization. Global Advisory Report, Part 1. Wkly Epidemiol Rep 65:5–12Google Scholar
  163. WHO/UNICEF (1989) Joint WHO/UNICEF statement on early immunization for HIV-infected children. Global programme on AIDS and expanded programme on immunization. Wkly Epidemiol Rec 7:48Google Scholar
  164. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS (2007) Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369:191–200PubMedGoogle Scholar
  165. Wong-Chew RM, Islas-Romero R, Garcia-Garcia ML, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gomez JL (2004) Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 189:254–257PubMedGoogle Scholar
  166. Wong-Chew RM, Islas-Romero R, Garcia-Garcia ML, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gomez JL (2006) Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 24:683–690PubMedGoogle Scholar
  167. Wyde PR, Stittelaar KJ, Osterhaus AD, Guzman E, Gilbert BE (2000) Use of cotton rats for pre-clinical evaluation of measles vaccines. Vaccine 19:42–53PubMedGoogle Scholar
  168. Yang K, Mustafa F, Valsamakis A, Santoro JC, Griffin DE, Robinson HL (1996) Early studies on DNA-based immunizations for measles virus. Vaccine 15:888–892Google Scholar
  169. Young LW, Smith DI, Glasgow LA (1970) Pneumonia of atypical measles. Residual nodular lesions. Am J Roentgenol 110:439–448Google Scholar
  170. Zhu Y, Fennelly G, Miller C, Tarara R, Saxe I, Bloom B, McChesney M (1997) Recombinant Bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant Rhesus macaques from measles virus pneumonia. J Infect Dis 176:1445–1453PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

There are no affiliations available

Personalised recommendations